APPLICATION
ANDA202280
TYPE
ANDA
ORIGINAL APPROVAL
2012-09-12
LATEST ACTION
2022-06-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
ESCITALOPRAM OXALATEPrescription
ESCITALOPRAM OXALATE EQ 20MG BASE · TABLET · ORAL
ESCITALOPRAM OXALATEPrescription
ESCITALOPRAM OXALATE EQ 5MG BASE · TABLET · ORAL
ESCITALOPRAM OXALATEPrescription
ESCITALOPRAM OXALATE EQ 10MG BASE · TABLET · ORAL
Approval history
2022-06-08Labeling · Supplement 19 · standardAP
2022-06-08Labeling · Supplement 13 · standardAP
2022-06-08Labeling · Supplement 8 · standardAP
2015-10-28Labeling · Supplement 6 · standardAP
2013-07-31Labeling · Supplement 3 · standardAP
2012-09-12OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.